Trader Brian Jones on Twitter: "7:08 am ET *Surface Oncology And Merck To Collaborate On Immuno-Oncology Study Evaluating SRF617, Targeting CD39 In Combination With KEYTRUDA (pembrolizumab) In Solid Tumor Patients(Benzinga)" / Twitter

7:08 am ET *Surface Oncology And Merck To Collaborate On Immuno-Oncology Study Evaluating SRF617, Targeting CD39 In Combination With KEYTRUDA (pembrolizumab) In Solid Tumor Patients(Benzinga)